Olema Pharmaceuticals, Inc. OLMA Unpaid Issuance Costs Related To Follow On Offering And Two Thousand Twenty Four Private Placement
Unpaid Issuance Costs Related To Follow On Offering And Two Thousand Twenty Four Private Placement at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept olma:UnpaidIssuanceCostsRelatedToFollowOnOfferingAndTwoThousandTwentyFourPrivatePlacement.
The official record: Olema Pharmaceuticals, Inc.’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →
Ask your AI about Olema Pharmaceuticals, Inc.'s unpaid issuance costs related to follow on offering and two thousand twenty four private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s unpaid issuance costs related to follow on offering and two thousand twenty four private placement?
- Olema Pharmaceuticals, Inc. (OLMA) reported unpaid issuance costs related to follow on offering and two thousand twenty four private placement of $144.5K in Q4 2025.
- How has Olema Pharmaceuticals, Inc.'s unpaid issuance costs related to follow on offering and two thousand twenty four private placement changed year-over-year?
- Olema Pharmaceuticals, Inc.'s unpaid issuance costs related to follow on offering and two thousand twenty four private placement decreased by 91.1% year-over-year, from $1.63M to $144.5K.
- What does unpaid issuance costs related to follow on offering and two thousand twenty four private placement mean?
- This represents costs incurred in connection with equity offerings that have been accrued but not yet paid in cash at the reporting date. It provides visibility into the total cost of capital raises that will impact future cash flows. Investors use this to reconcile total financing costs against the gross proceeds of an offering.